CU Logo University of Colorado Anschutz Medical Campus
Back to Results

Accelerating Medicines Partnership: Autoimmune and Immune-Mediated Disease (AIM) Rheumatoid Arthritis

Primary Objective

The goal of the Accelerating Medicines Partnership (AMP) research study is to better understand the molecular and cellular characteristics of Rheumatoid Arthritis (RA) to help develop better therapies for people with RA.

Is This Study For You?

Let's Get Started!

Description

If you participate you will be asked to come in for a screening to determine eligibility for a synovial biopsy of your wrist, knee, or ankle. You will also be asked to complete health questionnaires and have your blood drawn. You may be compensated up to $305 for completion of 3 visits over a 24-week period.

Details
Age
Adult
Eligibility
Subjects must be 18 years old or older Subjects must meet 2010 ACR/EULAR classification criteria or erosion consistent with RA Subjects must be less than 1 year from diagnosis of Rheumatoid Arthritis (RA) Subjects must be positive for anti-CCP or Rheumatoid Factor Subjects must have 1 or more swollen or tender joint Subjects cannot be on prednisone of more than 10mg once a day for more than 7 days leading up to enrollment Subjects may not be taking hydroxychloroquine (Plaquenil) for more than 2 weeks prior to enrollment Subjects may not be taking Methotrexate (MTX) for more than 2 weeks prior to enrollment
Locations

Barbara Davis Center
University of Colorado Hospital

Principal Investigator
Photograph of Larry Moreland

Larry Moreland

Study ID

Protocol Number: 23-0022

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers